Xeris Biopharma Holdings, Inc. (XERS) Stock Forecast & Price Prediction 2025, 2030, 2040, and 2050
Stay updated on Xeris Biopharma Holdings, Inc. (XERS) stock with short-term forecast for year 2025 and long-term price prediction for 2025 - 2050. Access historical performance, see analyst ratings, and follow the latest Xeris Biopharma Holdings, Inc. news and developments.
1 Month Prediction
$5.32 [28.82%]
3 Month Prediction
$5.85 [41.70%]
6 Month Prediction
$6.37 [54.14%]
1 Year Prediction
$6.21 [50.36%]
3 Year Prediction
$7.87 [90.44%]
5 Year Prediction
$9.34 [126.10%]
About Xeris Biopharma Holdings, Inc.
Xeris Biopharma Holdings, Inc. is a biopharmaceutical company that develops and commercializes innovative therapies for endocrinology, neurology, and gastroenterology. Their key products include Gvoke for severe hypoglycemia, Recorlev for Cushing's syndrome, and Keveyis for primary periodic paralysis. Xeris also has a pipeline led by XP-8121 for hypothyroidism.
The company uses its XeriSol and XeriJect technology platforms to create ready-to-use solutions across various therapeutic areas.
The company was founded in 2005 and headquartered in Chicago, Illinois.
Xeris Biopharma Holdings, Inc. (XERS) Historical Performance
IPO Date
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) went public on 06 October, 2021.
Change
Since inception, XERS has decreased by 78.24%. In the last 5 years, XERS has risen from $2.70 to $4.13, a massive 52.96% increase since 2020.
Historical Highs and Lows
In the past 5 years, the stock reached a high of $5.93 and a low of $1.24.
52 Week Range
$1.69
$4.5
The current price $4.13 is near the 52-week high, which means that the stock is overbought.
XERS Stock Price History
Based on XERS stock's historical price data, this table shows how the stock has performed in the last 6 years. Since 2019, the XERS stock has fallen from $1.95 - $6.37 to $3.56 - $4.13, which is down -61.55%. Currently, the stock follows downward trend.
Here, we have calculated stock range of XERS, indicating the highs and lows for each year, the average price based on the daily closing prices each year, and the change% from the average price.
| Year | Stock Price | Avg Price | Change% | Year Change |
|---|---|---|---|---|
| 2020 | $1.95 - $6.37 | $4.16 | -58.35 | 1 Year Change |
| 2021 | $1.86 - $5.45 | $3.43 | -65.66 | 2 Year Change |
| 2022 | $1.33 - $2.56 | $1.86 | -81.38 | 3 Year Change |
| 2023 | $1.24 - $2.62 | $2.04 | -79.58 | 4 Year Change |
| 2024 | $1.75 - $3.39 | $2.67 | -73.27 | 5 Year Change |
| 2025 | $3.56 - $4.13 | $3.84 | -61.55 | 6 Year Change |
XERS Price Performance
6-Month Performance
XERS stock jumped by 28.26% in the last six months.
1-Year Performance
The stock has trended upwards by 136.00% in the past year.
3-Year Performance
In the last 3 years, the stock has soared by 69.26%.
5-Year Performance
In the last 5 years, the stock has gone up by 52.96%.
According to Xeris Biopharma Holdings, Inc.'s historical data, below graph gives us the exact picture of how the XERS stock has performed year-over-year. Here, Each bar on the graph represents a particular year that illustrates how the stock's price changed from one year to the next.
YoY Performance
In the last five years, the stock has shown positive growth in 2 years and a decline in 3 years.
2020
30.21% ↓
2021
40.45% ↓
2022
54.61% ↓
2023
76.69% ↑
2024
44.26% ↑
NOTE: Green bars indicate that the stock has risen compared to the previous year, while red bars show that the stock has fallen.
Xeris Biopharma Holdings, Inc. (XERS) Financials & Stock Analysis
Total Revenue
Quarterly Revenue: $54.27 M (Q3)
Revenue for Q3 ending 30th September, 2024 increased 12.91% compared to Q2 ending 30th June, 2024.
Annual Revenue: $187.36 M (1Y)
Revenue for trailing 12 months increased 14.30% year over year from 31st December, 2023.
If compared to the last 5 years, the revenue has gone up from $20.43 million to $187.36 million, a 816.86% change.
Market Capitalization
Xeris Biopharma Holdings, Inc. has a market capitalization of $615.70M, which places XERS in the small-cap category.
Fundamental Analysis
EPS: $-0.11 (Q3), $-0.45 (1Y)
EPS increased 10.00% since last quarter, and decreased 35.71% since last year.
Net Income: $-15.74 M (Q3), $-62.26 M (1Y)
Net Income increased 4.89% since last quarter, and decreased 34.23% since last year.
Free Cash Flow: $-8.39 M (Q3), $-49.29 M (1Y)
Free Cash Flow decreased 21.90% since last quarter, and decreased 52.34% since last year.
Net Profit Margin: -29.00% (Q3), -33.23% (1Y)
Net Profit Margin decreased 7.10% since last quarter, and decreased 42.46% since last year.
Below, we have listed 12 key indicators for Fundamental analysis for XERS stock. These indicators help you understand Xeris Biopharma Holdings, Inc.'s financial health, earnings and growth potential, and make a decision if the stock is a good long-term investment or not.
|
|
Technical Analysis
Here, we have listed 5 key indicators for Technical Analysis for XERS stock. These indicators help investors study past price movements and trading volumes to forecast future price changes, and find the right time when to buy, sell or hold the stock.
| Technical Indicators | Value |
|---|---|
| SMA20 | $3.74 |
| SMA50 | $3.56 |
| SMA200 | $2.93 |
| RSI | 67.55 |
| Beta | 1.21 |
SMA20 < Current Price
This signals XERS stock is in short-term bullish momentum.
SMA50 < Current Price
This signals XERS stock is in mid-term bullish momentum.
SMA200 < Current Price
This signals XERS stock is in long-term bullish momentum.
Sentiment Based on Technical Analysis
Based on 8 technical analysis indicators, the overall sentiment for XERS stock is Bullish. Out of all indicators, 5 indicates bullish signals, 1 signals bearish trends and 3 gives neutral trends. The XERS stock forecast was last updated on 07 March, 2025.
Xeris Biopharma Holdings, Inc. (XERS) Stock Price Prediction and Forecast
According to short-term forecast, the stock is expected to rise to $6.51 by the end of 2025, and can reach around $5.80 to $5.79 in 2026. And, the long-term forecast suggests that the stock may further jump to $8.16 - $5.92 in 2028, and $9.85 - $9.89 by 2031. So, the XERS stock shows a strong upward trend in the next several years.
Short-term XERS Stock Price Prediction & Forecast
| Date | Forecasted Price | Change% |
|---|---|---|
| 2025-04 | $5.32 | 28.81% |
| 2025-05 | $5.85 | 41.65% |
| 2025-06 | $5.85 | 41.65% |
| 2025-07 | $6.08 | 47.22% |
| 2025-08 | $6.40 | 54.96% |
| 2025-09 | $6.37 | 54.24% |
| 2025-10 | $5.96 | 44.31% |
| 2025-11 | $6.02 | 45.76% |
| 2025-12 | $6.51 | 57.63% |
In 2025, the XERS stock price is expected to fluctuate between $5.32 and $6.51. According to the monthly forecast, the stock could rise to $6.51 by December 2024. If compared to the XERS's current price, the stock could gain 57.63% by the end of this year.
Long-term XERS Stock Price Prediction & Forecast
| Year | Year Start | Year Mid | Year End | Change% |
|---|---|---|---|---|
| 2026 | $5.80 | $5.35 | $5.79 | 40.19% |
| 2027 | $7.68 | $6.65 | $7.28 | 76.27% |
| 2028 | $8.16 | $7.24 | $5.92 | 43.34% |
| 2029 | $9.05 | $6.87 | $6.36 | 54.0% |
| 2030 | $6.61 | $9.58 | $7.52 | 82.08% |
| 2031 | $9.85 | $10.05 | $9.89 | 139.47% |
| 2032 | $11.52 | $11.08 | $11.55 | 179.66% |
| 2033 | $9.54 | $9.46 | $14.64 | 254.48% |
| 2034 | $13.25 | $12.19 | $12.40 | 200.24% |
| 2035 | $13.48 | $15.06 | $12.84 | 210.9% |
| 2036 | $13.50 | $18.96 | $13.86 | 235.59% |
| 2037 | $13.65 | $17.65 | $14.28 | 245.76% |
| 2038 | $14.72 | $13.33 | $11.42 | 176.51% |
| 2039 | $15.48 | $11.90 | $15.98 | 286.92% |
| 2040 | $14.06 | $18.36 | $15.23 | 268.77% |
| 2041 | $16.75 | $15.68 | $13.43 | 225.18% |
| 2042 | $18.23 | $21.41 | $17.59 | 325.91% |
| 2043 | $20.21 | $16.12 | $18.58 | 349.88% |
| 2044 | $19.94 | $21.44 | $17.23 | 317.19% |
| 2045 | $22.36 | $24.49 | $19.57 | 373.85% |
| 2046 | $21.45 | $16.20 | $22.48 | 444.31% |
| 2047 | $20.61 | $18.92 | $25.51 | 517.68% |
| 2048 | $21.39 | $27.04 | $25.20 | 510.17% |
| 2049 | $17.43 | $20.48 | $22.83 | 452.78% |
| 2050 | $26.65 | $17.09 | $21.67 | 424.7% |
| 2051 | $28.15 | $27.30 | $22.59 | 446.97% |
Xeris Biopharma Holdings, Inc. (XERS) Stock Price Prediction & Forecast 2025
At the start of 2025, the XERS stock was at $3.56. Today, it is trading at $4.13, which is 16.01% increase from price at the beginning of the year. By the end of this year, you can expect the stock to reach to $6.51 by December 2025 with a 57.63% change.
Xeris Biopharma Holdings, Inc. (XERS) Stock Price Prediction & Forecast 2026 - 2030
In the next five years, there will be a significant appreciation in the XERS stock. During this period, the XERS's price is forecasted to shift from $5.80 to $7.52, which is 29.66% gain.
In 2026, the stock would possibly open at $5.80, descends to $5.35 by mid-year, and wraps up at $5.79, reflecting a 40.30% increase from today's price. Further moving to 2030, the stock can kick off the year at $6.61, drop to $9.58 by mid-year, and finish at $7.52, which is 82.08% change from current price.
Xeris Biopharma Holdings, Inc. (XERS) Stock Price Prediction & Forecast 2031 - 2040
During this period, the stock would move from $9.85 to $15.23, which is up 139.38%
In 2031, we can expect XERS to fluctuate between $9.85 and $9.89, a shift indicating a 139.38% gain by year-end compared to current price. And Until 2040, XERS can likely vary from $14.06 to $15.23. By the end of 2040, the stock could record a 268.67% rise from today's stock price.
Xeris Biopharma Holdings, Inc. (XERS) Stock Price Prediction & Forecast 2041 - 2050
According to long-term forecast, the XERS stock can see an an upturn from $16.75 to $21.67 in this period. In 2041, the stock can experience a low of $15.68 by mid-year, closing the year at $13.43. This results in a 279.59% increase from today.
Moving towards the end of 2050, XERS is projected to open the year at $26.65. The stock may dip to $17.09 during mid-year and finish the year at $21.67. Compared to the stock's current price, this translates to an overall gain of 424.71% by 2050.
Become a member
Get the latest news right in your inbox. We never spam!
XERS Competitors
| Ticker | Company | Market Cap | Price | 1m Change | Forecast |
|---|---|---|---|---|---|
| TNYA | Tenaya Therapeutics, Inc. | - | $0.46 | -54.95% ▼ | $790.53 ▲ |
| MRSN | Mersana Therapeutics, Inc. | - | $0.54 | 4.07% ▲ | $519.39 ▲ |
| PSTV | Plus Therapeutics, Inc. | - | $1.44 | 97.26% ▲ | $70.11 ▲ |
| NTLA | Intellia Therapeutics, Inc. | - | $9.10 | -9.86% ▼ | $208.86 ▲ |
| ONVO | Organovo Holdings, Inc. | - | $1.27 | 252.78% ▲ | -3.29 ▼ |
Last updated Mar 07 at 8:56 PM
XERS : Buy, Sell Or Hold?
Analyst Ratings
Based on 4 analysts, 0 rated as a strong buy, 3 recommended a buy, 1 suggested a hold, 0 advised a sell, and 0 indicated a strong sell.So, according to analyst ratings, the recommendation for XERS stock is Buy.
Expert Analysis
According to XERS short-term and long-term forecast, Xeris Biopharma Holdings, Inc. shares are projected to go up by 424.7%, and reach a value of $21.67 per share by 2050.
As per technical analysis, indicators show a Bullish sentiment, while Fear & Greed Index stands at 85.71428571428571, which signals Greed. Also, XERS has recorded 12/30 green days, which reflects a 54.54545454545454% positivity rate with a price volatility of 0.03%.
Plus, Price-to-Earnings (P/E) ratio of 0 suggests that XERS stock is undervalued. So, Based on XERS prediction and analysis, it may be the best time to buy XERS stock right now.
Disclaimer: Stock predictions, forecasts and price targets provided for "XERS” are solely for informational and educational purposes and should not be treated as investment or financial advice. Always conduct your own research or consider consulting with a financial advisor before making any investment decisions.